Chief Executive Officer
Oliver is a experienced business leader with a strong technical background and has worked at the leading edge of the point of care diagnostics industry for over 30 years. He has held key positions in numerous start-ups and Blue-Chip multinationals and has a recognised track record of bringing category defining and disruptive Point of Care diagnostics products to market.
Prof Damion Corrigan
Founder & Chief Technical Officer
Prof Damion is a founder of Aureum and inventor of the first two Aureum IP filings. He also holds an academic position as LGC Professor in Measurement Science for Health in the Department of Pure and Applied Chemistry at the University of Strathclyde. His academic research focuses on development of new electrochemical biosensors and their application towards the diagnostic challenges faced in modern healthcare provision.
Prof Steve Howell
Non Executive Chairman
Steve joins Aureum Diagnostics as a non executive Chairman where he has over twenty five years’ life science and diagnostics experience. His passion is helping build and grow companies bringing them to profitability and supporting management teams to build great businesses of which they can be proud.Read More
He founded Innova Partnerships in 2006 and has been instrumental in creating over a dozen life science start ups and has raised in excess of £100m financing. Steve has been involved in exiting 3 businesses returning value back to shareholders.
Steve was made Visiting Professor of Commercial Innovation at King’s College London in 2015. Formerly, he held senior positions in diagnostics companies, Alere Inc and Unipath Ltd, and in Unilever plc.
Professor David Onions
David Onions, PhD FMedSCi DVMS(hon) FRSA FRSE, is an investor in biomedical companies and former Chief Medical Officer of Invitrogen/Life Technologies (now Thermo Fisher). He founded 2 biotechnology companies (Q-One Biotech and BioOutsource) which exited for a total of $100M and was involved in the buy-out of BioReliance which acquired by Sigma-Aldrich (now Merck KGaA).Read More
He was formerly a member of the board of BioReliance, VP of its commercial operations and the Chief Scientific Officer of the company. Prior to that he was a founder and President of Q-One Biotech Inc., a company involved in the GMP production and safety evaluation of biotechnology products. The company was awarded the Scottish Council for Development & Industry Award 2002 and the Biotech Scotland Award 2002. In 2003 the company was acquired by Invitrogen (now Thermo-Fisher) where David Onions became the Chief Medical Officer, overseeing the company’s developments of clinically based molecular programs.
Prior to his commercial activities David was Professor of Veterinary Pathology (Virology) at the University of Glasgow and Director of the Leukaemia Research Fund’s Human Virus Centre.
David Onions is a member or, former member, of several advisory groups including the UK Advisory Committee on Release of GMOs Into the Environment (ACRE), the FDA xenotransplantation advisory committee, The World Health Organisations Expert Advisory Panel on Biological Standardization and The UK Medical Research Council Stem Foundation.
He has been awarded the Norman Hall Gold Medal for Research into Animal Diseases from the Royal College of Veterinary Surgeons, the Animal Health Trust Award for Outstanding Scientific Achievement and The British Veterinary Association’s Dalrympel-Champney Cup and Medal for contributions to veterinary science.
In 2005 he was awarded the Scottish Enterprise award for Leading Individual Contribution to Life Sciences in 2005 and the Invitrogen’s employee of the year (Quest) Award 2005. In 2006 he received an Honorary Doctorate (DVMS) from the University of Glasgow for services to biotechnology and veterinary medicine.
Dr John Shillingford
Clinical Trial and Regulatory Adviser
Dr John Shillingford, PhD, holds both a B.Sc. in Biochemistry and a Ph.D. in Biochemical Pharmacology from the University of Surrey.
For the past eight years John has provided a consultancy service to global firms on the development of clinical drug trials and MedTech devices.Read More
Until 2011 and its sale, he held senior global roles at Averion International Corporation, including President of Averion GmbH, President of Averion Europe and Executive Vice President and Global Head of Clinical Operations.
Prior to Averion, he served as Managing Director and Vice President of Clinical Operations of Imform Gmbh.
John has extensive experience of clinical trial design and implementation across the whole of Europe and has successfully commenced and managed operations in Central and Eastern Europe. He has worked in all phases of drug development and has managed clinical research projects in Eastern and Western Europe, North America on behalf of clients from Japan, the USA and Europe. He has over 25 years of Pharmaceutical and Contract Research industry experience.
In addition to his board duties, John’s role at Afon Technology is to oversee the clinical trial activities. His considerable expertise in this sector will ensure that all the trials are designed to strict guidelines to satisfy the appropriate global medical directives.
Chief Operating Officer
As chief operating officer at Aureum, Tessa Ogle is responsible for the operations of the company. She brings more than 17 years of experience to Aureum. Her experience and leadership have been focused on developing and delivering technology-driven business services and solutions, providing outstanding client service, and driving profitable revenue growth.Read More
Prior to joining Aureum, Tessa was the CEO of an energy charity in the UK where she transformed their business model and enhanced brand recognition. She spent 10 years working on some of the largest multi-billion-dollar oil and gas projects around the world and in 2013 was recognised as a business leader in her field winning the Telstra Business Women’s Awards for both Private and Corporate Sector and the Young Business Woman of the Year Awards. This recognised her 7-fold business growth of $50 million energy business she ran for a global engineering firm.
Dr Richard Bowker
Director of Research and Development
Dr Richard Bowker is responsible for overseeing all aspects of research and development within Aureum. He leads a team of researchers who are working together to develop Aureum’s breakthrough point of care diagnostics platform to meet rapidly evolving global healthcare needs. Richard holds a PhD in Epigenetics and has over 10 years experience in developing point of care diagnostics.Read More
Working in multiple start-ups, he has grown teams to develop POC diagnostic products for multiple target markets, following CE and FDA regulatory requirements. Richard is passionate about translating novel ideas into real-world diagnostic products.